Abstract
Nanoparticles have unique properties and high design flexibility, which are thought to be safe, site-specific, and efficient drug delivery systems. However, nanoparticles as exogenous materials can provide recognition and be eliminated by the body’s immune system, which considerably restricts their applications. To overcome these drawbacks, natural cell membrane coating method has attracted great attention in the field of drug delivery systems, which can prolong nanoparticles blood circulation time and avoiding the capture as well as elimination by the body immune system. Biomimetic nanoparticles via a top-down approach can avoid the laborious group modified engineering and keep the integrity of cell membrane structure and membrane antigens, which can be endowed with unique properties, such as immune escape, longer blood circulation time, targeting delivery and controlling drugs sustain-release. At the present research, erythrocyte membrane, cancer cell membrane, platelet membrane, lymphocyte membrane and hybrid membrane have been successfully coated into the surface of nanoparticles to achieve biological camouflage. Thus, integrating various kinds of cell membranes and nanoparticles into one system, the biomimetic nanoparticles can inherit unique biofunction and drug delivery properties to exhibit tumor targeting-delivery and antitumor outcomes. In this article, we will discuss the prospects and challenges of some basic cell membrane cloaking nanoparticles as a drug delivery system for cancer therapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Nanoparticle-based drugs delivery system for disease treatment can enhance drugs accumulation at the lesion sites through retention and permeability effect, which can overcome complex biological environment to enhance therapeutic effects and avoid unnecessary side effects [1, 2]. However, considerable efforts have been devoted to nanoparticles. The exploitation of nanoparticles with optimized properties still have some challenges, such as post-nanoparticles entry to the blood circulation. This can be easily eliminated by the liver, spleen, reticuloendothelial system, and body immune system, resulting in a short half-life time, and limited nanoparticles accumulated at the lesion sites [3, 4].
Although the development of nanoengineering and modifying biomaterials on the surface of nanoparticles have achieved remarkable progress, the unanticipated material properties can negatively influence the function of nanoparticles in physiologically relevant systems [5, 6]. Thus, targeting ability, stability and biocompatibility are the three basic elements for the ideal nanoparticle. In recent years, a new type of bionic nanoparticle has been composited by the biologically derived cell membrane (versus cells and vesicles) coated nanoparticles cores, which can surpass the limit of the traditional surface modification approach [7]. Cell membrane biomimetic nanoparticles provide a top-down method to design a multifunctional drug delivery system. This is done by utilizing the complexity and versatility of the cell membrane to cloak nanoparticles and transfer the inherent characteristic of the cell membrane to the surface of the nanoparticle to execute a particular function [8].
As an effective and simple biomimetic strategy, cell membrane camouflaged nanoparticles can keep their membrane structure and antigens and realize special functions, including prolonging blood circulation time, immune escape, and specific recognition [9,10, Erythrocyte membranes undergo cloaking to prolong nanoparticles in the blood circulation time, however do not have any targeting ability against cancer cells [28, 29]. To date, some approaches have been made to improve the targeting ability by surface decoration with targeting molecules. These fabricate progress are complicated, and surface modifications can activate the body's immune system to some extent [30,31,32]. More evidence illustrates that cancer cells have unique targeting delivery and immune escape ability due to homologous cancer cells easy aggregation and interaction with the receptor and molecular (galectin-3, the endothelium-expressed β-galactoside-binding protein, tumor-associated Thomsen-Frieden Reich glycoantigen) on the surface of cancer cells [33, 34]. Cancer cells exhibit strong cell–cell communication and escape immune attack ability in the blood based on these merits. Thus, cancer cell membrane (CCM) biomimetic nanoparticles can select accumulation and longer retention at the tumor areas based on the homologous targeting. As Fig. 2a shows, Chen et al. fabricated a core–shell indocyanine green (ICG) loading and cancer cell membrane cloaking nanoparticle (ICNPs) for theragnostic cancer nanoplatforms [35]. MCF-7 cells were incubated with ICNPs, ICG, and INPs (ICG/poly(lactic-co-glycolic acid)) for 2 h. A stronger fluorescence signal was detected in the cellular cytoplasm of the ICNPs group than in the other two groups. ICNPs were injected into the tumor-carrying nude mice to investigate biodistribution. Most ICNPs were accumulated at the tumor areas via homologous targeting. Only a small amount of ICNPs was detected in the kidney and liver due to MCF-7 cell membrane can disguise ICNPs as cells to decrease kidney and liver interception. ICNPs have high spatial resolution, deep penetration, and real-time dual-modal image monitoring, completely eradicating tumors without tumor relapse upon the combination with near-infrared light irradiation. The survival rate was 100% after 18 days of therapy. Besides, cancer cells generate high levels of glutathione (GSH), consuming ROS during PDT therapy and compromise cancer therapy outcomes [36]. Thus, ameliorating the tumor microenvironment to improve therapy efficiency should be a powerful approach for tumor therapy. As Fig. 2b shows, Min and his co-workers developed porphyrinic zirconyl-based MOFs nanoparticles, loading vascular endothelial growth factor receptor 2 inhibitor apatinib and wrapped with MnO2 to neutralize the intratumorally high levels of GSH. The surface was further coated with a 4T1 cancer cell membrane (aMMTm) [37]. After intravenous injection, aMMTm had longer blood half-time and accumulated at the tumor area via homotypic targeting. MnO2, as to reduce agent scavenger, can consume high levels of GSH at the tumor areas to enhance PDT outcomes. The reaction product Mn2+ can be used as a magnetic resonance imaging contrast agent to detect antiangiogenic drug delivery and distribution in vivo. The obtained multifunctional aMMTm nanosystem combined PDT can significantly enhance tumor outcomes and prolong the survival rate of 4T1 bearing mice. The CCM biomimetic approach provides a novel strategy to achieve great progress in cancer therapy. However, the CCM biomimetic approach has some shortcomings at the early stage, including the requirements of homologous cancer cells for incubation and prolonged time and post-progressing to obtain CCM. Although CCM biomimetic nanoparticles have some drawbacks, l believe CCM biomimetic nanoparticles are a simple and efficient approach to construct an ideal drug delivery system for cancer treatment in the future. Platelet originates from the cytoplasm of megakaryocytes. The surface of the platelet membrane expressed CD47, can inhibit immune elimination by the body’s immune system and prolong their circulation time in the body’s blood [38,39,40]. Moreover, platelet plays an important role in tumor metastasis, bacterial infection, thrombogenesis, immune escape, and other functions, due to the surface of platelet membrane having unique receptors, antigens, and proteins, such as CD59, P-selection, CD55, and glycoprotein (GP) Ib [41,42,43,44,45]. Thus, platelet membrane (PM) biomimetic nanoparticles can target delivery to injured vascular areas, surrounding and aggregating the tumor cells, due to the surface of PM retaining the integrity of various biomolecules. This can mediate a series of molecular interactions and promote their affinity between tumor cells and platelet membranes [46, 47]. As Fig. 3a shows, Hu et al. developed PM camouflaged core–shell nano vehicle (PM-NV), the nanogel core used to load drugs. The surface of PM was further decorated with protein drugs, which can achieve targeting delivery and site-specific releasing behavior [48]. Tumor necnosis factor-related apoptosis-inducing ligand (TRAIL) and doxorubicin (DOX) as the most important extracellular activators of apoptosis, were simultaneously incorporated into PM-NV (TRAIL-DOX-PM-NV) for tumor therapy. TRAIL-DOX-PM-NV can be endocytosed and digested after incubating with tumor cells, promoting DOX accumulation at the nuclei and improve tumor cell apoptosis. When administered into the tumor mice model, TRAIL-DOX-PM-NV has blood stability, targeting delivery, and immune escape ability, which can aggregate the tumor cells to inhibit cancer cell metastatic and enhance tumor therapy. After the platelet membrane is fused with other membranes, the obtained products inherit the function of the platelet membrane and retain the advantages of other membranes. As Fig. 3b shows, Liu and his co-workers designed a novel platelet membrane-lipid hybrid biomimetic pH-responsive nanoparticles (PEOz-liposome-DOX) to target delivery and accelerate drug release at tumor acidic environment [49]. During platelet membranes and the liposome fusion process, pH-sensitive lipid DSPE (1,2-dioleoyl-sn-glycero-3-phosphoethaNolamine)-PEOz and DOX were simultaneously incorporated into the hybrid membrane carrier, accelerating drug-release at acidic conditions. In mouse tumor models, PEOz-liposome-DOX nanoplatform significantly exhibited tumor accumulation capacity, longer half-time, and excellent anti-tumor effects compared to traditional nanoparticles without pH-responsive or traditional liposomes with pH-sensitive behavior. Platelet membrane biomimetic camouflage nanoparticles have stealthy and biofriendly behavior in the blood circulation, reducing cell uptake by macrophage cells, selective adhesion to damage vasculatures, and improved nanoparticles adherence to cancer cells or pathogens to improve therapy effect. Lymphocytes, including T cells, B cells, and NK cells as the typical immune cells, play a core role in the intrinsic immune system against pathogen infection and tumor progression [49]. The number of lymphocytes increases rapidly after being activated by various diseases, and have far longer half-time’s in the blood circulation [65]. However, the application and investigation of biomimetic nanoparticles are still at an infant stage. There exist various challenges and problems that need to be solved, including the source of the cell membrane, the fabrication process of biomimetic nanoparticles, and the safety, biocompatibility, targeting ability of these biomimetic nanoparticles in tumor therapy. Different cell membranes have different sources, such as erythrocytes and platelets, which come from the body's common and abundant blood cells where they can be easily obtained [66]. Tumor cell membrane and immune cell membranes however, require tedious fabrication process, including large samples, cultivation, and amplification in vitro [67]. Biomimetic nanoparticles as foreign materials can induce a robust immune response after injection into the body. Therefore, design and construction of homologous cell membrane-based biomimetic nanoparticles origin from the patients’ lesion areas should be considered. Uneven or incomplete coverage of nanoparticles may easily induce the body’s immune response to eliminate the biomimetic nanoparticles system. Thus, kee** the integrity of the cell membrane structure is an important problem to be considered during the fusion and extraction process [68]. At present, repeating the freeze–thaw process and the hypotonic treatment is the most common extraction approach to maintain the cell membrane's functions and integrity [69]. However, these current processes are still stagnant at the early research stage, which require more time and procedures to optimize until they meet the clinical applications. Safety and biocompatibility are the most important factors before approval for clinical application. Currently, cell membrane biomimetic technology exhibits good biocompatibility and targeting ability compared to other traditional modified methods. However, these trials are still staying at a simple and primary mice experiment, which require more in vivo detail experiments and information to illustrate. Above all, cell membrane biomimetic nanoparticles exhibit superior tumor therapy effects after being combined with the advantages of cell membrane and nanoparticles. After cell membranes are modified with targeting molecules and integrated with nanoparticles or other therapeutic agents, biomimetic nanoparticles can realize excellent tumor therapy outcomes. However, these works are still at the early stage, which require repeatability experimentation before clinical use. In summary, the cell membrane biomimetic approach has made a great contribution to tumor therapy. This article summarizes some types of cell membrane (erythrocyte membrane, cancer cell membrane, platelet membrane, and leukomonocyte membrane) biomimetic nanoparticles to endow them with longer blood circulation time, immune escape, and tumor targeting ability to realize favorable anti-tumor effects. However, the clinical application of biomimetic nanoparticles encounters many challenges to resolve, including complex fabrication process, unsuitable large-scale production, low yields, and difficult preservation. Overall, targeting delivery, excellent anti-tumor properties, prolonged circulation time, minimal side effects, and positive economic effects should be the elemental factors of the cell membrane biomimetic approach for translating into clinical utilization.Cancer Cell Membrane Biomimetic Nanoparticles
Platelet Mimicking Nanoparticles
Lymphocyte Biomimetic Nanoparticles
Conclusion
Availability of data and materials
Not applicable.
Abbreviations
- EM:
-
Erythrocyte membrane
- MOFs:
-
Metal–organic frameworks
- GOx:
-
Glucose oxidase
- TGZ@eM:
-
EM coated MOFs based biomimetic nanoparticles loading GOx and prodrug
- PDT:
-
Photodynamic therapy
- PSs:
-
Photosensitizer
- FA:
-
Folate acid
- TPP:
-
Triphenylphonium
- CCM:
-
Cancer cell membrane
- ICG:
-
Indocyanine green
- ICNPs:
-
ICG loading and cancer cell membrane cloaking nanoparticle
- GSH:
-
Glutathione
- ROS:
-
Oxygen reactive species
- NIR:
-
Near-infrared irradiation
- aMMTm:
-
A 4T1 cancer cell membrane
- GP:
-
Glycoprotein
- PM:
-
Platelet membrane
- PM-NV:
-
PM camouflaged core–shell nano vehicle
- DOX:
-
Doxorubicin
- N3 :
-
Azide
- BCN:
-
Bicyclononyne
- Ac4ManN-BCN:
-
BCN modified unnatural sugar
- lactic-co-glycolic acid:
-
ICG loading into poly
- NK:
-
Natural killer
- NKG2-D:
-
NK cells receptor ligands in cancer cells
- NKsomes:
-
NK cells membrane biomimetic nanocarrier
- DOX@NKsomes:
-
DOX was loaded into the core of NKsomes
References
Jelinkovaa P, Mazumdar A et al (2019) Nanoparticle-drug conjugates treating bacterial infections. J Control Release 307:166–185
Ding B, Zheng P et al (2020) MnOx nanospikes as nanoadjuvants and immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect. Angew Chem Int Ed 59:16381–16384
Wan S-S, Cheng Q et al (2019) A Mn(III)-sealed metal−organic framework nanosystem for redox-unlocked tumor theranostics. ACS Nano 13:6561–6571
He Q, Liu J, Li W, Liu Z et al (2018) Towards improvements for penetrating the blood-brain barrier-recent progress from a material and pharmaceutical perspective. Cells 7:1–21
Kroll AV, Fang RH, Zhang L (2017) Biointerfacing and applications of cell membrane-coated nanoparticles. Bioconjug Chem 28:23–32
Luk BT, Zhang L (2015) Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release 220:600–607
Zhang P, Liu G, Chen X (2017) Nanobiotechnology: cell membrane-based delivery systems. Nano Today 13:7–9
Dehaini D et al (2017) Erythrocyte-platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater 29:1606209
Li SY et al (2017) Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplified bioreductive therapy. Biomaterials 142:149–161
Chena H-Y, Deng J et al (2020) Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy. Acta Biomater 112:1–13
Pei Q, **uli Hu et al (2018) Light-activatable red blood cell membrane-camouflflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano 12:1630–1641
Balasubramanian V et al (2017) Biomimetic engineering using cancer cell membranes for designing compartmentalized nanoreactors with organelle-like functions. Adv Mater 29:1605375
Min H, Wang J et al (2019) Biomimetic metal-organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy. Adv Mater 31:1808200
Li S-Y, Cheng H et al (2017) Cancer cell membrane-coated biomimetic platform for tumor targeted photodynamic therapy and hypoxia-amplifified bioreductive therapy. Biomaterials 142:149–161
Balasubramanian V et al (2017) Biomimetic engineering using cancer cell membranes for designing compartmentalized nanoreactors with organelle-like functions. Adv Mater 29:11
Liu B et al (2019) RBC membrane camouflaged prussian blue nanoparticles for gamabutolin loading and combined chemo/photothermal therapy of breast cancer. Biomaterials 217:119301
Wang C et al (2017) Red blood cells for glucose-responsive insulin delivery. Adv Mater 29:18
Gao W et al (2013) Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater 25:3549–3553
Zhang L et al (2018) Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy. ACS Nano 12:10201–10211
Liang K et al (2016) Enzyme encapsulation in zeolitic imidazolate frameworks: a comparison between controlled co-precipitation and biomimetic mineralisation. Chem Commun (Camb) 52:473–476
Celli JP et al (2010) Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev 110:2795–2838
Konan YN, Gurny R, Allemann E (2002) State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 66:89–106
Sun Q et al (2019) O2-generating metal-organic framework-based hydrophobic photosensitizer delivery system for enhanced photodynamic therapy. ACS Appl Mater Interfaces 11:36347–36358
Ding H et al (2015) Erythrocyte membrane-coated NIR-triggered biomimetic nanovectors with programmed delivery for photodynamic therapy of cancer. Nanoscale 7:9806–9815
Markov DE et al (2010) Human erythrocytes as nanoparticle carriers for magnetic particle imaging. Phys Med Biol 55:6461–6473
Rahmer J et al (2013) Nanoparticle encapsulation in red blood cells enables blood-pool magnetic particle imaging hours after injection. Phys Med Biol 58:3965–3977
Antonelli A et al (2013) Red blood cells as carriers in magnetic particle imaging. Biomed Tech (Berl) 58:517–525
Nathanael AJ, Oh TH (2020) Biopolymer coatings for biomedical applications. Polymers (Basel) 12:12
Piao JG et al (2014) Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 8:10414–10425
Bertrand N et al (2014) Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25
Cheng H et al (2015) Complementary hydrogen bonding interaction triggered co-assembly of an amphiphilic peptide and an anti-tumor drug. Chem Commun (Camb) 51:6936–6939
Wang C et al (2013) Structural basis for molecular recognition at serotonin receptors. Science 340:610–614
Fang RH et al (2014) Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 14:2181–2188
Zhu JY et al (2016) Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett 16:5895–5901
Chen Z et al (2016) Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dual-modal imaging and photothermal therapy. ACS Nano 10:10049–10057
Tian XT et al (2019) GSH-activated MRI-guided enhanced photodynamic- and chemo-combination therapy with a MnO2-coated porphyrin metal organic framework. Chem Commun (Camb) 55:6241–6244
Min H et al (2019) Biomimetic metal-organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy. Adv Mater 31:1808200
Doshi N et al (2012) Platelet mimetic particles for targeting thrombi in flowing blood. Adv Mater 24:3864–3869
Liu X et al (2014) Platelet-inspired multiscaled cytophilic interfaces with high specificity and efficiency toward point-of-care cancer diagnosis. Small 10:4677–4683
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590
Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134
Chung AW et al (2004) Platelet-leukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br J Pharmacol 143:845–855
Labelle M, Begum S, Hynes RO (2014) Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci USA 111:3053–3061
Kieffer N, Phillips DR (1990) Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 6:329–357
Yeaman MR (2010) Platelets in defense against bacterial pathogens. Cell Mol Life Sci 67:525–544
Fitzgerald JR, Foster TJ, Cox D (2006) The interaction of bacterial pathogens with platelets. Nat Rev Microbiol 4:445–457
Tomczynska M et al (2018) The potential contribution and role of a blood platelets in autoimmune thyroid diseases. J Cell Mol Med 22:6386–6390
Quanyin Hu et al (2015) Anticancer platelet-mimicking nanovehicles. Adv Mater 27:7043–7050
Dahlberg CI et al (2015) Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol 6:605
Liu W, Yan Q, **a C, Wang X, Kumar A, Wang Y et al (2021) Recent advances in cell membrane coated metal–organic frameworks (MOFs) for tumor therapy. J Mater Chem B 9:4459–4474
Tonn T et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563–1570
Romanski A et al (2016) CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies. J Cell Mol Med 20:1287–1294
Zhai Y et al (2017) Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics 7:2575–2592
Coulie PG et al (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146
Han Y et al (2019) T cell membrane mimicking nanoparticles with bioorthogonal targeting and immune recognition for enhanced photothermal therapy. Adv Sci (Weinh) 6:1900251
Knorr DA et al (2014) Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 26:161–172
Suck G, Linn YC, Tonn T (2016) Natural killer cells for therapy of leukemia. Transfus Med Hemother 43:89–95
Battella S, Cox MC, Santoni A, Palmieri G (2016) Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. J Leukoc Biol 99:87–97
Langers I et al (2012) Natural killer cells: role in local tumor growth and metastasis. Biologics 6:73–82
Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27:5932–5943
Hanna N (1982) Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev 1:45–64
Aryal S et al (2017) Membrane fusion-mediated gold nanoplating of red blood cell: a bioengineered CT-contrast agent. ACS Biomater Sci Eng 3:36–41
Pitchaimani A, Nguyen TDT, Aryal S (2018) Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. Biomaterials 160:124–137
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2018) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10:625–632
Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563–1570
Li B, Wang F, Gui L, He Q, Yao Y, Chen H (2018) The potential of biomimetic nanoparticles for tumor-targeted drug delivery. Nanomedicine 13:2099–2118
Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO et al (2013) Biomimetic functionalization with leukocyte membranes imparts cell like functions to synthetic particles. Nat Nanotechnol 8:61–68
Chen H-Y, Jiang Deng Yu, Wang C-Q, Li X, Dai H-W (2020) Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy. Acta Biomater 112:1–13
**a Q, Zhang Y, Li Z, Hou X, Feng N (2019) Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B 9:675–689
Acknowledgements
Not applicable.
Funding
None.
Author information
Authors and Affiliations
Contributions
XZ made substantial contributions to the conception, paper collecting, and analyzing of the work, CY final approval of the version to be published. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Zhao, X., Yan, C. Research Progress of Cell Membrane Biomimetic Nanoparticles for Tumor Therapy. Nanoscale Res Lett 17, 36 (2022). https://doi.org/10.1186/s11671-022-03673-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s11671-022-03673-9